Paper - WANFANG MED ONLINE

You Position: Home > Paper

Belimumab: targeted therapy for systemic lupus erythematosus

( views:816, downloads:533 )

Author:: No author available

Journal Title:: International Journal of Dermatology and Venereology

Issue:: 6

DOI:: 10.3760/cma.j.issn.1673-4173.2014.06.006

Key Word:: 红斑狼疮,系统性;贝利木单抗;分子靶向治疗;Lupus erythematosus,systemic;Belimumab;Molecular targeted therapy

Abstract： Systemic lupus erythematosus (SLE) is a systemic autoimmune disease,whose exact pathogenesis is not fully clear as yet.The abnormal activation of B cells plays an important role in the development of SLE,and B cell-activating factor (BAFF) is critical for the abnormal activation of B cells.Belimumab is a human monoclonal antibody which can selectively recognize and block soluble BAFF.The efficacy and safety of belimumab have been confirmed for the treatment of SLE in randomized,double-blind,large-scale clinical trials.As a biological agent with high efficacy,few side effects and high tolerability,belimumab is a promising drug for SLE.

Reference

[1]McCleary,S.,Schweighoffer,E.,Cantrell,D.,etc.The BAFF Receptor Transduces Survival Signals by Co-opting the B Cell Receptor Signaling Pathway[J].2013,38(3).
[2]Uy,E.A.,Zouali,M..Belimumab therapy in systemic lupus erythematosus[J].2013,27(3).
[3]Navarra SV,Guzman RM,Gallacher AE,etc.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.[J].2011,377(9767).
[4]Tekstra,J.,Bijlsma,J.W.J.,Luijten,K.M.A.C.,etc.The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment[J].2012,11(5).
[5]Yang, Shu,Li, Jian-Yong,Xu, Wei.Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma[J].2014,91(2).
[6]Dennis GJ.Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.[J].2012,91(1).
[7]Mackay, Ian R.,Mackay, Fabienne,Fairfax, Kirsten.BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus[J].2012,64(7).
[8]Zhong J,Ryel J,Recta V,etc.Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.[J].2008,58(8).
[9]J, Zhang,V, Roschke,K P, Baker,etc.Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.[J].2001,166(1).
[10]Scholz,J.L.,Oropallo,M.A.,Sindhava,V.,etc.The role of B lymphocyte stimulator in B cell biology: Implications for the treatment of lupus[J].2013,22(4).
[11]McCarthy,E.M.,Lee,R.Z.,Gabhann,J.N.,etc.Elevated B lymphocyte stimulator levels are associated with increased damage in an irish systemic lupus erythematosus cohort[J].2013,52(7).
[12]Tschopp J,Schneider P,Baetscher M,etc.Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.[J].1999,190(11).
[13]Parodis,I.,Axelsson,M.,Gunnarsson,I..Belimumab for systemic lupus erythematosus: A practice-based view[J].2013,22(4).
[14]Ramanujam M,Davidson A.BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?[J].2008,223(0).
[15]LaCava,A..Targeting the BLyS-APRIL signaling pathway in SLE[J].2013,148(3).
[16]Furie R,Petri M,Zamani O,etc.A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.[J].2011,63(12).
[17]Schneider P,Mackay F.Cracking the BAFF code.[J].2009,9(7).
[18]Khan,W.N.,Wen,R.,Podd,A.,etc.Critical role of B cell lymphoma 10 in BAFF-regulated NF-κB activation and survival of anergic B cells[J].2012,189(11).
[19]Zhong J,Baker KP,Lappin P,etc.Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.[J].2006,91(2).
[20]Richard Furie,William Stohl,Ellen M Ginzler,etc.Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus[J].2008,10(5).
[21]Hsieh,H.-J.,Wallace,D.J.,Oates,J.C.,etc.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial[J].2010,62(1).
[22]Koss MN,Pricop L,Bixler SA,etc.Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF.[J].2006,177(4).
[23]Chugh,P.K..Lupus: Novel therapies in clinical development[J].2012,23(3).
[24]Maria Trachana,Artemis Koutsonikoli,Evagelia Farmaki,etc.Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.[J].2013,33(3).